睿知中国医院研究地图
候选清单

正在招募乳腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Organoid-based Functional Precision Therapy for Advanced Breast Cancer

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由广东省人民医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方广东省人民医院Guangdong Provincial People's Hospital广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06102824,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 80 岁;性别:不限

    登记记录的入选字段

  2. Pathologically documented unresectable locally advanced or metastatic breast cancer that:

    入选标准第 3 条

    All subjects must have a recent tumor sample after the most recent treatment regimen or agree to undergo a tissue biopsy prior to randomization.

    入选标准第 7 条

    Successful acquisition of a solid tumor biopsy sample containing ≥ 20% tumor content, or malignant effusion sample (e.g., pleural, or pericardial effusion or ascites) confirmed to contain malignant cells.

    入选标准第 15 条

  3. Normal organ and bone marrow function measured within 28 days prior to administration of study treatment.

    入选标准第 11 条

    Male and female subjects of reproductive/childbearing potential must have a documented negative pregnancy test within 2 weeks prior to randomization and agree to acceptable birth control (non-hormonal) during and up to 6 months after trial therapy.

    入选标准第 12 条

    Ineligible for all 5 of the study treatments either because of previously having received treatment in the advanced or metastatic setting or having a contraindication to treatment.

    排除标准第 1 条

    Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤1 or baseline.

    排除标准第 10 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

    入选标准第 6 条

  5. Presence of at least 1 measurable lesion based on computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1

    入选标准第 5 条

  6. Has multiple primary malignancies within 3 years, except adequately resected nonmelanoma skin cancer, curatively treated in situ disease, or contralateral breast cancer.

    排除标准第 9 条

  7. Is pregnant or breastfeeding or planning to become pregnant.

    排除标准第 15 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06102824,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Must be competent and able to comprehend, sign, and date a written informed consent form (ICF) before performance of any study-specific procedures or tests.
  2. Men or women ≥18 years old.
  3. Pathologically documented unresectable locally advanced or metastatic breast cancer that:
  4. Documented radiologic progression (during or after most recent treatment).
  5. Presence of at least 1 measurable lesion based on computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1
  6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  7. All subjects must have a recent tumor sample after the most recent treatment regimen or agree to undergo a tissue biopsy prior to randomization.
  8. No visceral crisis.
  9. Life expectancy of ≥ 6 months as assessed by the treating investigator.
  10. Complete all required baseline laboratory tests and imaging examinations within 28 days before randomization.
  11. Normal organ and bone marrow function measured within 28 days prior to administration of study treatment.
  12. Male and female subjects of reproductive/childbearing potential must have a documented negative pregnancy test within 2 weeks prior to randomization and agree to acceptable birth control (non-hormonal) during and up to 6 months after trial therapy.
  13. No absolute contraindication for invasive procedures to obtain samples for organoid generation.
  14. Sufficient material for organoid generation: biopsied samples (length>1cm, 2-3 pieces), surgically resected samples (>1cm×1cm×0.5cm, weight>200mg), malignant effusion samples collected by thoracentesis, abdominocentesis or lumbar puncture (pleural fluid>50mL, ascites>50mL, cerebrospinal fluid≥4 tubes with each tube ≥4mL).
  15. Successful acquisition of a solid tumor biopsy sample containing ≥ 20% tumor content, or malignant effusion sample (e.g., pleural, or pericardial effusion or ascites) confirmed to contain malignant cells.

排除标准:Exclusion Criteria:

  1. Ineligible for all 5 of the study treatments either because of previously having received treatment in the advanced or metastatic setting or having a contraindication to treatment.
  2. Documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious.
  3. Known active central nervous system metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth (patients with history of CNS metastases or spinal cord compression are eligible if they are clinically and radiologically stable for at least 4 weeks before first dose of trial treatment and have not required high-dose steroid treatment in the last 4 weeks).
  4. Inflammatory breast cancer.
  5. Has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug product.
  6. Major surgery within 3 weeks of starting study treatment: patients must have recovered from any effects of any major surgery.
  7. Systemic treatment with anticancer therapy, antibody-based therapy, hormonal therapy, or radiotherapy within 3 weeks before study treatment.
  8. Participation in a therapeutic clinical study within 3 weeks before study treatment, or current participation in other investigational procedures.
  9. Has multiple primary malignancies within 3 years, except adequately resected nonmelanoma skin cancer, curatively treated in situ disease, or contralateral breast cancer.
  10. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤1 or baseline.
  11. Substance abuse or medical conditions such as clinically significant cardiac or pulmonary diseases or psychological conditions, that would, in the opinion of the Investigator, increase the safety risk to the subject or interfere with the subject's participation in the clinical study or evaluation of the clinical study results.
  12. Has known human immunodeficiency virus infection or active hepatitis B or C infection.
  13. Has an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.
  14. Has gastrointestinal disorders likely to interfere with absorption of the study medication.
  15. Is pregnant or breastfeeding or planning to become pregnant.
  16. Any concurrent condition which in the Investigator's opinion makes it inappropriate for the patient to participate in the trial or which would jeopardize compliance with the protocol.

引自 ClinicalTrials.gov, NCT06102824, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06102824,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06102824